Thrombocytes And IndividuaLization of ORal Antiplatelet Treatment After Percutaneous Coronary Intervention.

Trial Profile

Thrombocytes And IndividuaLization of ORal Antiplatelet Treatment After Percutaneous Coronary Intervention.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2014

At a glance

  • Drugs Prasugrel (Primary) ; Clopidogrel
  • Indications Acute coronary syndromes; Cardiovascular disorders; Coronary artery disease; Thrombosis
  • Focus Pharmacodynamics
  • Acronyms TAILOR
  • Most Recent Events

    • 03 Sep 2013 Primary endpoint 'Platelet-aggregation' has been met.
    • 03 Sep 2013 Results presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.
    • 23 Mar 2011 Actual initiation date (September 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top